Biotechnology
Triastek and Siemens announce strategic collaboration to accelerate digital transformation of the pharmaceutical industry
NANJING, China, March 17, 2022 /PRNewswire/ -- Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies a...
2022-03-17 21:24
3140
Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc.
2022-03-17 20:00
2218
I Peace triples GMP cell manufacturing by expanding CDMO facility
PALO ALTO, Calif., March 14, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.The facility's expansion, ...
2022-03-15 03:22
2000
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 14, 2022 /PRNewwire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announc...
2022-03-15 00:06
2466
MediLink Therapeutics closes US$70 million Series B financing
SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of aUS$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highligh...
2022-03-14 20:50
2907
WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics
SHANGHAI, March 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, has been recognized as the Industry Top-Rated Company in 2022 by Sustainalytics, a global provider of Environmental, Social and Governance (ESG) related research,ratings and data. This ...
2022-03-14 20:30
3019
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine
SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech...
2022-03-14 20:00
2721
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...
2022-03-10 07:00
2277
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of t...
2022-03-09 07:47
4046
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held Apr...
2022-03-09 06:58
5111
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage...
2022-03-09 05:30
2525
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...
2022-03-08 08:00
2197
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) * Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 7, 2022 /PR...
2022-03-08 08:00
2144
Singleron Acquires Proteona
NANJING/SUZHOU, China and COLOGNE, Germany and SINGAPORE, March 7, 2022 /PRNewswire/ -- Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisitio...
2022-03-07 23:00
2565
Alterity Therapeutics to Present at the 34th Annual Roth Conference
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D.,...
2022-03-07 20:59
2493
TCI Enters into Strategic Alliance with VeCollal(R) and CDMO the World's First, Science-based vegan collagen alternative
TAIPEI, March 7, 2022 /PRNewswire/ -- Today TCI (8436TT) announced its strategic alliance with VeCollal® , the well-knownBelgium based vegan collagen alternative company which has joined hands with TCI. The VeCollal® vegan collagen alternative has been designed to have the identical amino acid pr...
2022-03-07 16:00
3048
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
CHENGDU, China, March 7, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (2162.HK) is pleased to announce that the shares of the Company have been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect with effect fromMarch 7, 2022, pursuant to the announcement issued by the Shenzhen St...
2022-03-07 15:57
2959
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...
2022-03-04 21:00
3609
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...
2022-03-04 09:30
2958
InxMed Raised $50 million in Series B Financing to Advance Innovative Therapies to Drug-resistance Cancers
NANJING, China, March 3, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $50 million in Series B Fi...
2022-03-04 08:00
2290
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 316 media titles]
2026-05-28 15:06Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 291 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 290 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 285 media titles]
2026-05-28 14:10
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7504
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
7114
